IP Library Granted Patent US 7,279,157
Granted Patent B2
US 7,279,157 · App. 10/975,883 · Granted Oct 9, 2007

Method for treating psoriasis by administering an anti-il-12 antibody

Assignee: Centocor, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,279,157
App. No.
10/975,883
Granted
Oct 9, 2007
Kind
B2
Abstract

The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Claims (5)

1. A method for treating psoriasis in an animal, comprising:

contacting or administering a composition comprising an effective amount of an isolated anti-IL-12 antibody comprising a heavy chain variable region (V H ) of the amino acid sequence set forth in SEQ ID NO:7 and a light chain variable region (V L ) of the amino acid sequence set forth in SEQ ID NO:8, with, or to, said animal.

2. The method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal.

3. The method according to claim 1 , wherein said contacting or said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intraspinal, intrasynovial, rectal, buccal, sublingual, intranasal, and transdermal.

4. The method according to claim 1 , further comprising administering, prior, concurrently or after said contacting or administering step, at least one composition comprising an effective amount of at least one compound or protein selected from at least one of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, a stimulant, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Assignments (1)
CHANGE OF NAME Recorded Nov 17, 2011
From: CENTOCOR ORTHO BIOTECH, INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 027248/0434 →
Continuity (4)
Division 0992026200 · Aug 1, 2001
Provisional Application 6023682700 · Sep 29, 2000
Provisional Application 6022335800 · Aug 7, 2000
Related Publication 20050112127A1 · May 26, 2005